CN103204827B - 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途 - Google Patents

作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途 Download PDF

Info

Publication number
CN103204827B
CN103204827B CN201210189087.2A CN201210189087A CN103204827B CN 103204827 B CN103204827 B CN 103204827B CN 201210189087 A CN201210189087 A CN 201210189087A CN 103204827 B CN103204827 B CN 103204827B
Authority
CN
China
Prior art keywords
alkyl
formula
hydrogen
compound
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201210189087.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN103204827A (zh
Inventor
田红旗
季聪慧
刘春磊
黄功超
孔丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Kezhou Pharmaceutical Co ltd
Original Assignee
KECHOW PHARMA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201210189087.2A priority Critical patent/CN103204827B/zh
Application filed by KECHOW PHARMA Inc filed Critical KECHOW PHARMA Inc
Priority to CA2897259A priority patent/CA2897259C/en
Priority to NZ627631A priority patent/NZ627631A/en
Priority to PCT/CN2013/000037 priority patent/WO2013107283A1/en
Priority to AU2013201455A priority patent/AU2013201455B8/en
Priority to US14/372,731 priority patent/US9290468B2/en
Priority to JP2014551508A priority patent/JP6077006B2/ja
Priority to EP13738359.2A priority patent/EP2804855B1/en
Priority to HK15103824.9A priority patent/HK1203486B/en
Publication of CN103204827A publication Critical patent/CN103204827A/zh
Application granted granted Critical
Publication of CN103204827B publication Critical patent/CN103204827B/zh
Priority to US15/050,045 priority patent/US9937158B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201210189087.2A 2012-01-17 2012-06-08 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途 Active CN103204827B (zh)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN201210189087.2A CN103204827B (zh) 2012-01-17 2012-06-08 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
HK15103824.9A HK1203486B (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof
PCT/CN2013/000037 WO2013107283A1 (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof
AU2013201455A AU2013201455B8 (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof
US14/372,731 US9290468B2 (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof
JP2014551508A JP6077006B2 (ja) 2012-01-17 2013-01-16 ベンゾ複素環式化合物およびその使用
CA2897259A CA2897259C (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof
NZ627631A NZ627631A (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof
EP13738359.2A EP2804855B1 (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof
US15/050,045 US9937158B2 (en) 2012-01-17 2016-02-22 Benzoheterocyclic compounds and use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210014021 2012-01-17
CN201210014021.X 2012-01-17
CN201210189087.2A CN103204827B (zh) 2012-01-17 2012-06-08 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN103204827A CN103204827A (zh) 2013-07-17
CN103204827B true CN103204827B (zh) 2014-12-03

Family

ID=48752254

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201210189087.2A Active CN103204827B (zh) 2012-01-17 2012-06-08 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
CN201210189086.8A Active CN103204822B (zh) 2012-01-17 2012-06-08 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
CN201210190520.4A Active CN103204825B (zh) 2012-01-17 2012-06-08 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201210189086.8A Active CN103204822B (zh) 2012-01-17 2012-06-08 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
CN201210190520.4A Active CN103204825B (zh) 2012-01-17 2012-06-08 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途

Country Status (7)

Country Link
US (2) US9290468B2 (https=)
EP (1) EP2804855B1 (https=)
JP (1) JP6077006B2 (https=)
CN (3) CN103204827B (https=)
CA (1) CA2897259C (https=)
NZ (1) NZ627631A (https=)
WO (1) WO2013107283A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104710417B (zh) * 2013-12-11 2020-09-08 上海科州药物研发有限公司 氮杂吲哚类衍生物及其合成方法
CN105384738B (zh) * 2014-08-21 2017-08-29 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
CN105859543A (zh) * 2016-05-06 2016-08-17 蚌埠中实化学技术有限公司 一种2,6-二氟-4-溴苯甲酰氯的制备方法
CN111205244B (zh) * 2018-11-22 2023-08-18 上海科技大学 噻唑并环类化合物、其制备方法、中间体和应用
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN113440616A (zh) * 2020-03-25 2021-09-28 上海科州药物研发有限公司 Ras或raf突变型癌症的联合疗法
PE20260035A1 (es) * 2023-02-10 2026-01-09 Shanghai Kechow Pharma Inc Polimorfo como inhibidor de la proteina quinasa mek, metodo de preparacion y uso del mismo
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025242163A1 (zh) * 2024-05-23 2025-11-27 上海科州药物股份有限公司 蛋白激酶mek抑制剂的盐及其用途
WO2025261499A1 (zh) * 2024-06-20 2025-12-26 上海科州药物股份有限公司 蛋白激酶Mek抑制剂苯并噻唑的颗粒药物组合物
CN120463660A (zh) * 2024-09-30 2025-08-12 上海科州药物股份有限公司 大规模制备妥拉美替尼及其中间体的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056789A1 (en) * 2002-12-20 2004-07-08 Warner-Lambert Company Llc Mek inhibiting oxa- and thia-diazol-2-yl phenylamine derivates
WO2007121154A2 (en) * 2006-04-11 2007-10-25 Janssen Pharmaceutica, N.V. Substituted benzothiazole kinase inhibitors
CN101213196A (zh) * 2005-07-01 2008-07-02 赛诺菲-安万特 吡啶并[2,3-d]嘧啶衍生物，它们的制备，在治疗中的用途
CN101605783A (zh) * 2007-01-05 2009-12-16 赛诺菲-安万特 作为药物、药物组合物尤其作为ikk抑制剂的新型n,n’-2,4-二苯胺基嘧啶衍生物及其制备
CN101678014A (zh) * 2007-05-21 2010-03-24 Sgx药品公司 杂环激酶调节剂

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
CA2290509A1 (en) 1997-07-01 1999-01-14 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
NZ501276A (en) 1997-07-01 2000-10-27 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders
US6120451A (en) 1998-12-31 2000-09-19 General Electric Company Ultrasound color flow display optimization by adjustment of threshold
HUP0105092A3 (en) 1999-01-13 2003-12-29 Warner Lambert Co 1-heterocycle substituted diarylamines and medicaments containing them
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
EP1144372B1 (en) 1999-01-13 2005-11-30 Warner-Lambert Company Llc Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
EP1150950A2 (en) 1999-01-13 2001-11-07 Warner-Lambert Company Anthranilic acid derivatives
CA2355470C (en) * 1999-01-13 2008-09-30 Warner-Lambert Company Benzoheterocycles and their use as mek inhibitors
JP2000204079A (ja) * 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
CA2377092A1 (en) * 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
BR0109188A (pt) 2000-03-15 2003-03-18 Warner Lambert Co Diarilaminas 5-amida substituìdas como inibidores de mex
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
EP1482944A4 (en) 2002-03-13 2006-04-19 Array Biopharma Inc NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
SG2013013339A (en) * 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
WO2005007616A1 (en) 2003-07-23 2005-01-27 Warner-Lambert Company Llc Diphenylamino ketone derivatives as mek inhibitors
CA2532067C (en) 2003-07-24 2010-12-21 Stephen Douglas Barrett N-methyle-substituted benzamidazoles
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2005046665A1 (en) 2003-11-13 2005-05-26 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and a erbb1/2 receptor inhibitor
CA2546353A1 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
SG177981A1 (en) 2005-05-18 2012-02-28 Array Biopharma Inc 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
WO2006134469A1 (en) 2005-06-14 2006-12-21 Warner-Lambert Company Llc Methods of preparing mek inhibitor
MX2008002114A (es) 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
HRP20110498T1 (hr) 2005-10-07 2011-08-31 Exelixis Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
EP1966155A1 (en) 2005-12-21 2008-09-10 AstraZeneca AB Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
MX2008013097A (es) 2006-04-18 2008-10-27 Ardea Biosciences Inc Piridona sulfonamidas y piridona sulfamidas como inhibidores de metiletilcetona.
CN101528231A (zh) 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 在癌症的治疗中使用pi3k和mek调控剂
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
GB0625691D0 (en) 2006-12-22 2007-01-31 Astrazeneca Ab Combination product
MX2009007661A (es) 2007-01-19 2009-12-14 Ardea Biosciences Inc Inhibidores de mek.
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
US20100130519A1 (en) 2007-04-13 2010-05-27 Stephen Robert Wedge Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
US7960567B2 (en) 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
FR2918785B1 (fr) 2007-07-13 2009-11-13 Lemer Prot Anti X Par Abrevati Materiau radioattenuateur, et procede pour l'obtention d'un tel materiau
UA99731C2 (ru) 2007-07-30 2012-09-25 Ардеа Биосайенсис, Инк Кристаллические полиморфные формы n-(ариламино)сульфонамидов как ингибиторы мэк, композиция (варианты) и применение
EP2231281A2 (en) 2007-12-12 2010-09-29 AstraZeneca AB Combination comprising a mek inhibitor and an aurora kinase inhibitor
GB0801081D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0801080D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
WO2009093008A1 (en) 2008-01-21 2009-07-30 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
CA2781218A1 (en) 2009-12-08 2011-06-16 Novartis Ag Heterocyclic sulfonamide derivatives
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
FR2967672B1 (fr) 2010-11-22 2012-12-28 Sanofi Aventis Derives de nitrobenzothiazoles, leur preparation et leurs applications therapeutiques
BR112013027096A2 (pt) 2011-04-21 2016-12-27 Gilead Sciences Inc compostos de benzotiazol e seu uso farmacêutico

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056789A1 (en) * 2002-12-20 2004-07-08 Warner-Lambert Company Llc Mek inhibiting oxa- and thia-diazol-2-yl phenylamine derivates
CN101213196A (zh) * 2005-07-01 2008-07-02 赛诺菲-安万特 吡啶并[2,3-d]嘧啶衍生物，它们的制备，在治疗中的用途
WO2007121154A2 (en) * 2006-04-11 2007-10-25 Janssen Pharmaceutica, N.V. Substituted benzothiazole kinase inhibitors
CN101605783A (zh) * 2007-01-05 2009-12-16 赛诺菲-安万特 作为药物、药物组合物尤其作为ikk抑制剂的新型n,n’-2,4-二苯胺基嘧啶衍生物及其制备
CN101678014A (zh) * 2007-05-21 2010-03-24 Sgx药品公司 杂环激酶调节剂

Also Published As

Publication number Publication date
CN103204822A (zh) 2013-07-17
EP2804855B1 (en) 2017-09-20
US20140371278A1 (en) 2014-12-18
HK1203486A1 (en) 2015-10-30
US9290468B2 (en) 2016-03-22
US20160235721A1 (en) 2016-08-18
JP2015503597A (ja) 2015-02-02
CN103204825A (zh) 2013-07-17
EP2804855A1 (en) 2014-11-26
AU2013201455A8 (en) 2016-04-14
WO2013107283A1 (en) 2013-07-25
CN103204822B (zh) 2014-12-03
AU2013201455B2 (en) 2015-07-23
AU2013201455C1 (en) 2016-01-21
CA2897259C (en) 2019-05-07
JP6077006B2 (ja) 2017-02-08
AU2013201455A1 (en) 2013-08-01
CA2897259A1 (en) 2013-07-25
US9937158B2 (en) 2018-04-10
CN103204825B (zh) 2015-03-04
CN103204827A (zh) 2013-07-17
EP2804855A4 (en) 2015-07-29
NZ627631A (en) 2016-10-28

Similar Documents

Publication Publication Date Title
CN103204827B (zh) 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
AU2024202573B2 (en) KRas G12C inhibitors
Cheng et al. Synthesis, antibacterial activities and molecular docking studies of peptide and Schiff bases as targeted antibiotics
TW202227397A (zh) 雙環的－雜環衍生物及相關用途
CA2954376C (en) Novel anxiolytic compounds
JP2013503190A (ja) Ｒａｆ阻害化合物およびその使用方法
WO2018145621A1 (zh) 喹啉类化合物、其制备方法及其医药用途
JP2011500734A (ja) 新規なヒストンデアセチラーゼインヒビター、その調製方法および使用
JP2022509534A (ja) Ｂｅｔ阻害剤としてのヘテロ環式化合物
WO2013013614A1 (zh) 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
JP2013509412A (ja) 多標的キナーゼ阻害における新規な足場としてのイミダゾピリジン類
AU2020255702B2 (en) Quinolyl-containing compound and pharmaceutical composition, and use thereof
CN107987072B (zh) 作为crth2抑制剂的吲哚类化合物
TW479058B (en) 2,7-substituted octahydro-pyrrolo[1,2-a]pyrazine derivatives
JP2022550489A (ja) スルホ置換ビアリール化合物又はその塩並びにその調製方法及び使用
CN105384738B (zh) 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
TW202233593A (zh) 乙醯胺基－苯基四唑衍生物及其使用方法
CA2923175C (en) Liver x receptor (lxr) modulators
CN103958526B (zh) 嘧啶二胺类衍生物、其制备方法及其在医药上的应用
WO2021228215A1 (zh) 可用作RORγ调节剂的联芳基类化合物
Jin et al. Design, synthesis, and evaluation of thiazolecarboxamide derivatives as stimulator of interferon gene inhibitors
CN105228609A (zh) 新的转录因子调节剂
WO2012099785A2 (en) Modulators of tlr3/dsrna complex and uses thereof
CN116987073B (zh) 一种PI3Kα/HDAC6亚型选择性双重抑制剂及其应用
CN115260195B (zh) Egfr降解剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: SHANGHAI KEZHOU PHARMACEUTICAL RESEARCH + DEVELOPM

Free format text: FORMER OWNER: BINJIANG PHARMA, INC.

Effective date: 20140821

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 300457 BINHAI NEW DISTRICT, TIANJIN TO: 201203 PUDONG NEW AREA, SHANGHAI

TA01 Transfer of patent application right

Effective date of registration: 20140821

Address after: 201203 Shanghai Zhangjiang High Tech Park of Pudong New Area Cailun Road, room 714 No. 780

Applicant after: KECHOW PHARMA, Inc.

Address before: 300457 experimental building, Tianjin international biological medicine Joint Research Institute, 220 Dongting Road, Tianjin Binhai New Area Development Zone, N1701

Applicant before: TIANJIN BINJIANG PHARMACEUTICAL Inc.

C14 Grant of patent or utility model
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Room 714, No. 780 Cailun Road, Zhangjiang High tech Park, Pudong New Area, Shanghai, 201203

Patentee after: Shanghai Kezhou Pharmaceutical Co.,Ltd.

Country or region after: China

Address before: Room 714, No. 780 Cailun Road, Zhangjiang High tech Park, Pudong New Area, Shanghai, 201203

Patentee before: KECHOW PHARMA, Inc.

Country or region before: China